NCT05141890

Probiotics for Inflammation in Pediatric Chronic Pain

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: Medical College of Wisconsin · Academic / Other
• Sex: All
• Age: 13 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

To examine benefits of a probiotic for youth with chronic pain and a Body Mass Index \>=85th percentile.

Detailed description

The purpose of the current study: (1) examine whether a 7-11 week supplement of a single-strain probiotic (Lactobascillus Plantarum, Lp299v) reduces systemic inflammation; (2) determine whether reductions in systemic inflammation will correlate with reductions in pain, disability, mood impairment and changes in mechanical pain threshold and mechanical pain sensitization; (3) Explore whether reductions in systemic inflammation will correlate with reductions in other outcomes.

Conditions

• Chronic Pain
• Body Mass Index >=85th Percentile

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Lactobacillus Plantarum	Dietary Supplement: Lp299v. Lp299v is a commercially available probiotic supplement manufactured and distributed by Next Foods.

Timeline

• Start date: 2022-04-25
• Primary completion: 2024-08-01
• Completion: 2026-06-01
• First posted: 2021-12-02
• Last updated: 2026-01-12

Locations

1 site across 1 country: United States